xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.23262, Wiley Online Library on [02/01/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

10

KUANetal.

3. Morbidity related to orbital resection or orbitotomy............... 343 4. Morbidity related to intradural resection . 348 XXXII. QOL AFTER MULTIMODALITY TREATMENT FOR SINONASAL MALIGNANCIES................ 348 A. General QOL following multimodality treatment .................. 350 B. Morbidity following surgical treatment . . . 353 C. Morbidity following radiation treatment. . . 358 D. Morbidity following proton therapy . . . . . 359 E. Osteoradionecrosis . . . . . . . . . . . . . . 359 F. Morbidity following chemotherapy . . . . . 364 G. Morbidity following immunotherapy . . . . 365 XXXIII. SURVEILLANCE . . . . . . . . . . . . . 365 A. Timing and schedule . . . . . . . . . . . . 365 B. Role of assessment based on physical exam, signs, and symptoms. . . . . . . . . . . . . 370 C. Roleofendoscopy . . . . . . . . . . . . . . 371 D. Roleofimaging............... 372 E. Differences in surveillance practices based on histology................... 373 F. Surveillance of sinonasal malignancies . . . 373 G. Surveillance of inverted papilloma. . . . . . 373 XXXIV. RESEARCH OPPORTUNITIES AND FUTURE DIRECTIONS . . . . . . . . . . . . . 374 A. Basic/translational research opportunities . 375 B. Clinical and outcomes research opportunities 376 C. Public health/policy . . . . . . . . . . . . . 376 D. Diagnosis, workup, and staging . . . . . . . 376 E. Treatment strategies . . . . . . . . . . . . . 377 F. Survivorship, QOL, and long-term care . . . 377 XXXV. CONCLUSION............... 378 ACKNOWLEDGMENTS . . . . . . . . . . . . . . 378 CONFLICT OF INTEREST STATEMENT . . . . . . 378 ORCID........................ 378 REFERENCES.................... 379 A Introduction Sinonasal tumors, although traditionally rare, are now increasingly recognized as a highly morbid disease. These tumors pose unique challenges due to frequent involve ment of critical neurovascular structures, nonspecific signs and symptoms, and late-stage detection. Over the past decade, the field of sinonasal neoplasms and masses has grown rapidly, enhancing our knowledge of these diverse diseases. While previous literature mainly consisted of single-institution, retrospective reports, recent efforts have focused on multi-institutional studies and clinical trials, I EXECUTIVE SUMMARY

leading to improved evidence quality. This progress has been made possible by the collaboration and knowledge sharing among various specialists, including otolaryngol ogists, rhinologists, head and neck oncologists, medical and radiation oncologists, pathologists, radiologists, and neurosurgeons. In accordance with previously published consensus statements in the field of rhinology, 1–5 the International Consensus Statement on Allergy and Rhinology: Sinonasal Tumors (ICSNT) aims to bring together a globally repre sentative group of experts from different disciplines to pro vide an up-to-date summary and critical appraisal of the current evidence regarding the diagnosis, treatment, prog nosis, and outcomes of benign and malignant sinonasal tumors. ICSNT serves as a complementary resource to the 2019 International Consensus Statement on Endo scopic Skull Base Surgery (ICSB) 5 and updates the highly regarded 2010 European Position Paper (EPOS) on Endo scopic Management of Tumours of the Nose, Paranasal Sinuses and Skull Base. 6 It is important to note that ICSNT does not serve as practice guidelines but instead offers recommendations based on the best available evidence. Ultimately, individual treatment plans will depend on the expertise and preferences of the medical and surgical team, as well as patient factors and preferences. The goal of ICSNT is to provide clinicians with a valuable resource to enhance their understanding of specific tumors and aid in the development of tailored treatment plans. B Methods Using the established methodology of the prior Interna tional Consensus Statement on Allergy and Rhinology (ICAR) statements, topics encompassing the breadth of sinonasal neoplasms and masses were developed by the editorial team (JNP, ECK, EWW, NDA, DMB, NRL, SYS, MBW). These 48 topics were broadly classified under four sections: General Principles; Benign Lesions and Neo plasms; Malignant Neoplasms; and Morbidity, Quality of Life, and Surveillance. An effort was made to center on histopathology given its central role. International mul tidisciplinary expert authors then assembled teams and were assigned these topics. Areas of overlap with ICSB were updated and cross-referenced accordingly within the document. 5 A rigorous systematic review process was then undertaken, which included literature review, evidence based review (EBR), and evidence-based review with recommendations (EBRR) based on available literature (following the guidelines outlined by Rudmik and Smith 7 ). All authors were instructed to follow the Preferred Report ing Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, 8 and an aggregate grade of evidence